Tokyo Tape
Sign in
← Otsuka Holdings

Quarterly report · Q1

4578.TEDINET S100QQZ3
Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥1.74T2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥380.3bn2022-01-01 → 2022-03-31Cons.Revenue IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Operating income¥20.7bn2022-01-01 → 2022-03-31Cons.Operating profit loss IFRS
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥173.0bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥31.0bn2022-01-01 → 2022-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥133.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.3bn2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥24.2bn2022-01-01 → 2022-03-31Cons.Profit loss IFRS
Total assets¥3.13Tat 2023-03-31Cons.Assets IFRS
Total assets¥3.10Tat 2022-12-31Cons.Assets IFRS
Total assets¥2.89Tat 2022-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥811.5bnat 2023-03-31Cons.Liabilities IFRS
Total liabilities¥840.3bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥2.10Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥2.05Tat 2021-12-31dCons.Equity IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.23Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.07Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥423.4bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥211.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥57.7bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.6bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥22.8bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.5bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥34.6bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥246.82022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥42.862022-01-01 → 2022-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥246.782022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥42.72022-01-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥42.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥33.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥9.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥13.0bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥11.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥72.7bn
—segment totalrevenue2023-01-01 → 2023-03-31¥458.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥9.7bn
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-01-01 → 2022-03-31¥39.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-01-01 → 2022-03-31¥30.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-01-01 → 2022-03-31¥4.1bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥11.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2022-01-01 → 2022-03-31−¥235m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥11.3bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥17.3bn
—segment totalrevenue2022-01-01 → 2022-03-31¥389.1bn
—segment totalrevenue external2022-01-01 → 2022-03-31¥380.3bn
—segment totalrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
—segment totalsegment profit2022-01-01 → 2022-03-31¥32.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 706
ItemContextValueUnit
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember9654000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-9654000000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E21183-000PharmaceuticalsReportableSegmentMember303161000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E21183-000NutraceuticalsReportableSegmentMember103972000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E21183-000ConsumerProductsReportableSegmentMember8233000000JPY
Revenue IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember42630000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember457998000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-9654000000JPY
Revenue IFRSCurrentYTDDuration448344000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E21183-000PharmaceuticalsReportableSegmentMember72678000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E21183-000NutraceuticalsReportableSegmentMember11224000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E21183-000ConsumerProductsReportableSegmentMember2153000000JPY
Operating profit loss IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember3684000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember89740000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-12960000000JPY
Operating profit loss IFRSCurrentYTDDuration76779000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-05-12
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第16期第１四半期（自　2023年１月１日　至　2023年３月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)大塚ホールディングス株式会社
Company name in english cover pageFilingDateInstantOtsuka Holdings Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長兼CEO　　樋口　達夫
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都千代田区神田司町二丁目９番地（同所は登記上の所在地であり、実際の業務は下記の最寄りの連絡場所で行っております。）
Telephone number address of registered headquarter cover pageFilingDateInstant03－6717－1410
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)財務会計部長　新井　敏文
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区港南二丁目16番４号　品川グランドセントラルタワー12階
Telephone number nearest place of contact cover pageFilingDateInstant03－6717－1410
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)財務会計部長　新井　敏文
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE21183
Fund codeFilingDateInstant－
Security codeFilingDateInstant45780
Filer name in japaneseFilingDateInstant
Original text (Japanese)大塚ホールディングス株式会社
Filer name in englishFilingDateInstantOtsuka Holdings Co., Ltd.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Current fiscal year start dateFilingDateInstant2023-01-01
Current period end dateFilingDateInstant2023-03-31
Type of current periodFilingDateInstantQ1
Current fiscal year end dateFilingDateInstant2023-12-31
Previous fiscal year start dateFilingDateInstant2022-01-01

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass